Silexion Therapeutics (NASDAQ:SLXN) Issues Quarterly Earnings Results, Beats Estimates By $204.70 EPS

Silexion Therapeutics (NASDAQ:SLXN) issued its earnings results on Thursday. The company reported ($13.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($218.40) by $204.70, FiscalAI reports.

Silexion Therapeutics Stock Down 17.6%

Shares of NASDAQ SLXN traded down $0.57 during mid-day trading on Thursday, reaching $2.66. The company had a trading volume of 70,729 shares, compared to its average volume of 61,274. The business’s 50-day simple moving average is $5.83 and its 200 day simple moving average is $142.68. Silexion Therapeutics has a one year low of $2.57 and a one year high of $777.12.

Analysts Set New Price Targets

SLXN has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Friday, September 11th. Maxim Group cut Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

About Silexion Therapeutics

Silexion Therapeutics Ltd. (NASDAQ: SLXN) is an Israel-based clinical-stage biotechnology company developing RNA-based medicines for the treatment of solid tumors driven by mutations in the KRAS oncogene. The company’s technology is designed to selectively silence cancer-causing KRAS mutations while limiting exposure to healthy tissue. Silexion’s lead program, siG12D-LODER, is an investigational RNA interference therapy targeting the KRAS G12D mutation, which is frequently found in pancreatic and other difficult-to-treat cancers.